Heterogeneity of neuroanatomical patterns in prodromal Alzheimer’s disease: links to cognition, progression and biomarkers

Brain

Volumn 140, Issue 3, 2017, Pages 735-747

  Dong, Aoyan ^a   Toledo, Jon B ^a,b   Honnorat, Nicolas ^a   Doshi, Jimit ^a   Varol, Erdem ^a   Sotiras, Aristeidis ^a   Wolk, David ^a   Trojanowski, John Q ^a   Davatzikos, Christos ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Dementia; Magnetic resonance imaging; Mild cognitive impairment; Neuroanatomical heterogeneity; Pattern analysis

Indexed keywords

AMYLOID PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROANATOMY; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; TEMPORAL LOBE; VERY ELDERLY; VOXEL BASED MORPHOMETRY; WHITE MATTER; ANALYSIS OF VARIANCE; CLUSTER ANALYSIS; COGNITION DISORDERS; COMPLICATION; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; GENETICS; IMAGE PROCESSING; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; BIOMARKERS; CLUSTER ANALYSIS; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; PEPTIDE FRAGMENTS; PRODROMAL SYMPTOMS; TAU PROTEINS; WHITE MATTER;

EID: 85020429872     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww319     Document Type: Article

References (57)

1. Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, et al. Focal cortical presentations of Alzheimer’s disease. Brain 2007; 130: 2636–45.
2. Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011; 42: 722–7.
3. Ashburner J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage 2000; 11: 805–21.
4. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389–404.
5. Busatto GF, Diniz BS, Zanetti MV. Voxel-based morphometry in Alzheimer’s disease. Expert Rev Neurother 2008; 8: 1691–702.
6. Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996; 29: 162–73.
7. Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012; 6: 502–16.
8. Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol 2012; 11: 170–8.
9. Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, et al. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin 2014; 4: 164–73.
10. Davatzikos C, Genc A, Xu D, Resnick SM. Voxel-based morphometry using the RAVENS maps: methods and validation using simulated longitudinal atrophy. Neuroimage 2001; 14: 1361–9.
11. DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ. Anatomical mapping of white matter hyperintensities (wmh) exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke 2005; 36: 50–5.
12. Dong A, Honnorat N, Gaonkar B, Davatzikos C. CHIMERA: clustering of heterogeneous disease effects via distribution matching of imaging patterns. IEEE Trans Med Imaging 2016; 35: 612–21.
13. Doshi J, Erus G, Ou Y, Gaonkar B, Davatzikos C. Multi-atlas skull-stripping. Acad Radiol 2013; 20: 1566–76.
14. Doshi J, Erus G, Ou Y, Resnick SM, Gur RC, Gur RE, et al. MUSE: MUlti-atlas region segmentation utilizing ensembles of registration algorithms and parameters, and locally optimal atlas selection. Neuroimage 2016; 127: 186–95.
15. Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012; 6: 517–27.
16. Gorno-Tempini ML, Brambati SM, Ginex V, Ogar J, Dronkers NF, Marcone A, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology 2008; 71: 1227–34.
17. Habes M, Erus G, Toledo JB, Zhang T, Bryan N, Launer LJ, et al. White matter hyperintensities and imaging patterns of brain ageing in the general population. Brain 2016; 139 (Pt 4): 1164–79.
18. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med 2013; 368: 1326–34.
19. Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016; 87: 539–47.
20. Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685–91.
21. Jack CR, Wiste HJ, Weigand SD, Knopman DS, Mielke MM, Vemuri P, et al. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain 2015; 138: 3747–59.
22. Karas GB, Scheltens P, Rombouts SARB, Visser PJ, van Schijndel RA, Fox NC, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer’s disease. Neuroimage 2004; 23: 708–16.
23. Klöppel S, Stonnington CM, Chu C, Draganski B, Scahill RI, Rohrer JD, et al. Automatic classification of MR scans in Alzheimer’s disease. Brain 2008; 131: 681–9.
24. Lam B, Masellis M, Freedman M, Stuss DT, Black SE. Clinical, imaging, and pathological heterogeneity of the Alzheimer’s disease syndrome. Alzheimers Res Ther 2013; 5: 1.
25. Larner AJ. Getting it wrong: the clinical misdiagnosis of Alzheimer’s disease. Int J Clin Pract 2004; 58: 1092–4.
26. Li C, Gore JC, Davatzikos C. Multiplicative intrinsic component optimization (MICO) for MRI bias fi eld estimation and tissue segmentation. Magn Reson Imaging 2014; 32: 913–23.
27. McKeith IG, Fairbairn AF, Perry RH, Thompson P. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry 1994; 165: 324–32.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 2011; 77: 333.
29. Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage 2009; 44: 1415–22.
30. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015; 85: 296–302.
31. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011; 10: 785–96.
32. Nettiksimmons J, DeCarli C, Landau S, Beckett L; Alzheimer’s Disease Neuroimaging Initiative. Biological heterogeneity in ADNI amnestic mild cognitive impairment. Alzheimer’s Dement 2014; 10: 511–21.
33. Noh Y, Jeon S, Lee JM, Seo SW, Kim GH, Cho H, et al. Anatomical heterogeneity of Alzheimer disease based on cortical thickness on MRIs. Neurology 2014; 83: 1936–44.
34. Ossenkoppele R, Pijnenburg YAL, Perry DC, Cohn-Sheehy BI, Scheltens NME, Vogel JW, et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain 2015; 138: 2732–49.
35. Ou Y, Sotiras A, Paragios N, Davatzikos C. DRAMMS: deformable registration via attribute matching and mutual-saliency weighting. Med Image Anal 2011; 15: 622–39.
36. Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. JAMA Neurol 1999; 56: 303–8.
37. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74: 201–9.
38. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Core Team; 2016.
39. Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. Neuroimage 2010; 53: 1181–96.
40. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012; 61: 1402–18.
41. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197–204.
42. Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging 2009; 21: 239–51.
43. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403–13.
44. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011; 121: 597–609.
45. Shiino A, Watanabe T, Maeda K, Kotani E, Akiguchi I, Matsuda M. Four subgroups of Alzheimer’s disease based on patterns of atrophy using VBM and a unique pattern for early onset disease. Neuroimage 2006; 33: 17–26.
46. Thal DR, Rüb U, Orantes M, Braak H. Phases of Ab-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791–800.
47. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain 2013a; 136: 2697–706.
48. Toledo JB, Bjerke M, Chen K, Rozycki M, Jack CR, Weiner MW, et al. Memory, executive, and multidomain subtle cognitive impairment clinical and biomarker findings. Neurology 2015; 85: 144–53.
49. Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 2012; 124: 23–35.
50. Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun 2013b; 1: 65.
51. Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S, et al. Pathological -synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology. Acta Neuropathol 2016: 131: 393–409.
52. Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, Arnold SE, et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun 2014; 2: 26.
53. van der Flier WM, Pijnenburg YAL, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE "4 allele. Lancet Neurol 2011; 10: 280–8.
54. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, et al. Impact of the Alzheimer’s disease neuroimaging initiative, 2004 to 2014. Alzheimers Dement 2015; 11: 865–84.
55. Whitwell JL, Dickson DW, Murray ME, Weigand SD, Tosakulwong N, Senjem ML, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: a case-control study. Lancet Neurol 2012; 11: 868–77.
56. Wilson RS, Yu L, Trojanowski JQ, Chen E-Y, Boyle PA, Bennett DA, et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol 2013; 70: 1418–24.
57. Zanetti M, Ballabio C, Abbate C, Cutaia C, Vergani C, Bergamaschini L. Mild cognitive impairment subtypes and vascular dementia in community-dwelling elderly people: a 3-year follow-up study. J Am Geriatr Soc 2006; 54: 580–6.